Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

Spark Therapeutics surge premarket after getting FDA committee endorses its blindness treatment

There is currently no treatment for the disease, which causes childhood blindness
child in hospital
Luxturna has received orphan drug, breakthrough therapy and rare pediatric disease designations from the agency, the company said in a statement.

Spark Therapeutics Inc. (NASDAQ:ONCE) shares surged in premarket trade after a U.S. Food and Drugs Administration advisory committee recommended approval of its gene therapy treatment for a rare eye disease that causes blindness.

Its shares rose 6.03% at US$91.40 in premarket trade.

The committee voted unanimously to approve Luxturna (voretigene neparvovec) in the treatment of patients with biallelic RPE65-mediated inherited retinal disease.

No current treatment available

There is currently no treatment for the disease, which causes childhood blindness.

Luxturna has received orphan drug, breakthrough therapy and rare pediatric disease designations from the agency, the company said in a statement.

Although the committee's ruling is non-binding, it is taken into consideration by the FDA when reviewing drug applications.

The drug has also orphan product designation from the European Medicines Agency. Its marketing authorisation application for Luxturna was validated by the EMA, the company added.

View full ONCE profile View Profile

Spark Therapeutics Timeline

Related Articles

newspaper with word cancer magnified
July 11 2017
"In our view, the potential for SCIB1 [Scancell's skin cancer treatment], as already demonstrated by the survival data, is remarkable," said one broker recently
clinical-trial.jpg
June 30 2017
In all 200 suffers were recruited to the trial and all of them have now past the three month stage.
picture of doctor
September 06 2017
A Phase I clinical trial is to start later this year for the LOXL-2 inhibitor

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use